Chinese biotechnology and health care companies have become a steady source of initial public offerings in Hong Kong. Photo: Xinhua Chinese biotechnology and health care companies have become a steady source of initial public offerings in Hong Kong. Photo: Xinhua
Chinese biotechnology and health care companies have become a steady source of initial public offerings in Hong Kong. Photo: Xinhua
IPO

Chinese biotech, health care listings help Hong Kong IPO market to third place globally in first half as total number falls to five-year low

  • As the number of IPOs during the first half dropped to the lowest since 2016, Chinese biotech and health care issuers have helped buoy the market
  • Hong Kong’s bourse is expected to rank third globally in terms of IPO funds raised for the first half, slipping from second at the end of 2020

Topic |   IPO
Chinese biotechnology and health care companies have become a steady source of initial public offerings in Hong Kong. Photo: Xinhua Chinese biotechnology and health care companies have become a steady source of initial public offerings in Hong Kong. Photo: Xinhua
Chinese biotechnology and health care companies have become a steady source of initial public offerings in Hong Kong. Photo: Xinhua
READ FULL ARTICLE